MNI BRIEF: Canada Commits To Just One Of Three Fiscal Anchors

MNI BRIEF: German Insolvency Rate Slows, 2025 Pickup Expected

MNI BRIEF: Brazil Not Even Close To Fiscal Dominance - David

CORRECTED-MNI BRIEF: Brazil Inflation Rises To 4.87% In Nov

MNI China Daily Summary: Tuesday, December 10

EZ/UK T-Bill Calendar: 12-Month BOT Auction on Wednesday

EZ/UK Bond Supply Calendar: 4.25% Jul-34 Gilt Due Wednesday

MNI: US REDBOOK: DEC STORE SALES +4.2% V YR AGO MO

MNI EXCLUSIVE: EU-Mercosur Deal Close, But Likely Short-Lived - Officials

AUSTRALIA: 2025 Election Outcome Looking More Uncertain According To Newspoll

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Sanofi (SANFP: A1 pos / AA): Consumer Unit Sale

HEALTHCARE
BulletCredit Bullets
  • Said to be close to EUR 15.5bn deal for its over-the-counter unit
  • CD&R private equity will take 50% stake with Sanofi retaining the rest according to the FT, with a view to selling it over the next few years
  • The unit generates 10% of sales. Keeping half for now will at least guarantee the earning stability from that unit for a while.
  • Dupixent (25% of sales) goes off-patent around 2031. The company is seeking to boost its pipeline.
75 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Said to be close to EUR 15.5bn deal for its over-the-counter unit
  • CD&R private equity will take 50% stake with Sanofi retaining the rest according to the FT, with a view to selling it over the next few years
  • The unit generates 10% of sales. Keeping half for now will at least guarantee the earning stability from that unit for a while.
  • Dupixent (25% of sales) goes off-patent around 2031. The company is seeking to boost its pipeline.